JP2017526930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526930A5 JP2017526930A5 JP2017513509A JP2017513509A JP2017526930A5 JP 2017526930 A5 JP2017526930 A5 JP 2017526930A5 JP 2017513509 A JP2017513509 A JP 2017513509A JP 2017513509 A JP2017513509 A JP 2017513509A JP 2017526930 A5 JP2017526930 A5 JP 2017526930A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- binding protein
- rgma
- level
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 36
- 238000000034 method Methods 0.000 claims 21
- 102000023732 binding proteins Human genes 0.000 claims 15
- 108091008324 binding proteins Proteins 0.000 claims 15
- 208000015122 neurodegenerative disease Diseases 0.000 claims 14
- 230000004770 neurodegeneration Effects 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 8
- 238000001514 detection method Methods 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000012528 membrane Substances 0.000 claims 4
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 4
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 4
- 238000001262 western blot Methods 0.000 claims 4
- 238000011269 treatment regimen Methods 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 2
- 229960004419 dimethyl fumarate Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000012287 Prolapse Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 229940038717 copaxone Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229960004577 laquinimod Drugs 0.000 claims 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 238000001050 pharmacotherapy Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048745P | 2014-09-10 | 2014-09-10 | |
| US62/048,745 | 2014-09-10 | ||
| PCT/EP2015/070603 WO2016038084A1 (en) | 2014-09-10 | 2015-09-09 | Rgma fragment based diagnostic assay |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526930A JP2017526930A (ja) | 2017-09-14 |
| JP2017526930A5 true JP2017526930A5 (cg-RX-API-DMAC7.html) | 2018-10-18 |
| JP6879905B2 JP6879905B2 (ja) | 2021-06-02 |
Family
ID=54064367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513509A Active JP6879905B2 (ja) | 2014-09-10 | 2015-09-09 | ＲＧＭａ断片ベース診断アッセイ |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160069907A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3191847A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6879905B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113267630A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015314240A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017004883A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2956814A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX385216B (cg-RX-API-DMAC7.html) |
| TW (2) | TW201617612A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016038084A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156578A1 (en) * | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
| SG181563A1 (en) * | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| SG11202100561QA (en) | 2018-07-19 | 2021-02-25 | Univ Tokyo | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham |
| CN118697868A (zh) * | 2020-01-15 | 2024-09-27 | 国立大学法人大阪大学 | 糖尿病性自主神经障碍的预防或治疗剂 |
| CN112402554B (zh) * | 2020-10-26 | 2022-03-01 | 中国中医科学院广安门医院 | 一种治疗脑白质病的中药组合物及其应用 |
| US12306192B2 (en) | 2021-02-08 | 2025-05-20 | Cedars-Sinai Medical Center | Method of detecting cognitive impairment |
| WO2023004436A1 (en) * | 2021-07-23 | 2023-01-26 | Cedars-Sinai Medical Center | Methods and systems for early detection of ocular and/or neurological conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002519702A (ja) * | 1998-07-03 | 2002-07-02 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 神経変性の分別診断 |
| US7981420B2 (en) | 2000-12-22 | 2011-07-19 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. | Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| WO2011071059A1 (ja) * | 2009-12-09 | 2011-06-16 | 国立大学法人大阪大学 | Ｔ細胞活性化阻害剤、これを含有する医薬組成物およびｔ細胞活性化阻害物質のスクリーニング方法 |
| CA2807014A1 (en) * | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2012047706A2 (en) * | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| EP2723866B1 (en) * | 2011-06-22 | 2018-03-28 | Universite Laval | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease |
| ES2676725T3 (es) | 2012-01-27 | 2018-07-24 | AbbVie Deutschland GmbH & Co. KG | Composición y método para el diagnóstico y el tratamiento de enfermedades asociadas con la degeneración de las neuritas |
-
2015
- 2015-09-09 AU AU2015314240A patent/AU2015314240A1/en not_active Abandoned
- 2015-09-09 CN CN202110521844.0A patent/CN113267630A/zh active Pending
- 2015-09-09 CN CN201580048412.5A patent/CN107076757A/zh active Pending
- 2015-09-09 CA CA2956814A patent/CA2956814A1/en not_active Abandoned
- 2015-09-09 TW TW104129821A patent/TW201617612A/zh unknown
- 2015-09-09 JP JP2017513509A patent/JP6879905B2/ja active Active
- 2015-09-09 EP EP15759819.4A patent/EP3191847A1/en not_active Withdrawn
- 2015-09-09 MX MX2017003063A patent/MX385216B/es unknown
- 2015-09-09 TW TW109124697A patent/TW202119030A/zh unknown
- 2015-09-09 BR BR112017004883A patent/BR112017004883A2/pt not_active IP Right Cessation
- 2015-09-09 WO PCT/EP2015/070603 patent/WO2016038084A1/en not_active Ceased
- 2015-09-10 US US14/850,185 patent/US20160069907A1/en not_active Abandoned
-
2017
- 2017-03-08 MX MX2021009528A patent/MX2021009528A/es unknown
-
2019
- 2019-09-04 US US16/560,632 patent/US20200241012A1/en not_active Abandoned
-
2021
- 2021-03-02 US US17/190,135 patent/US20220018855A1/en not_active Abandoned
-
2022
- 2022-01-12 AU AU2022200160A patent/AU2022200160A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526930A5 (cg-RX-API-DMAC7.html) | ||
| Gasparotto et al. | Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment | |
| Laird et al. | High mobility group box protein‐1 promotes cerebral edema after traumatic brain injury via activation of toll‐like receptor 4 | |
| Whelan et al. | Developments in scalable strategies for detecting early markers of cognitive decline | |
| Huang et al. | Biofluid biomarkers of Alzheimer’s disease: progress, problems, and perspectives | |
| Creed et al. | Concussive brain trauma in the mouse results in acute cognitive deficits and sustained impairment of axonal function | |
| Tenembaum | Acute disseminated encephalomyelitis | |
| Nuzzo et al. | Inflammatory mediators as biomarkers in brain disorders | |
| CN106461645A (zh) | 外伤性脑损伤和神经退行性生物标记物、方法和系统 | |
| Shimizu et al. | Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier | |
| Wicker et al. | Serum amyloid A protein as a potential biomarker for severity and acute outcome in traumatic brain injury | |
| JP2024069651A (ja) | 神経障害のバイオマーカーとしてインフラマソームタンパク質を検出するための方法 | |
| JP2015508887A5 (cg-RX-API-DMAC7.html) | ||
| CN111788487A (zh) | 用于治疗眼病的预测性生物标记物 | |
| JP2009515183A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Irisin alleviates autoimmune uveitis through promoting retinal microglial M1 to M2 phenotypic polarization mediated by HIF-1α pathway | |
| Rommer et al. | Elevated levels of carbonyl proteins in cerebrospinal fluid of patients with neurodegenerative diseases | |
| Meltzer et al. | Updates and controversies in the management of acute optic neuritis | |
| Sbriscia et al. | miR-132-3p is down-regulated in plasma and CD171+ extracellular vesicles isolated from patients with mild Alzheimer’s disease | |
| Kang et al. | The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain | |
| JP2018523092A5 (cg-RX-API-DMAC7.html) | ||
| Rommer et al. | Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients | |
| Montague et al. | Advancements in multiple sclerosis | |
| EP4125999B1 (en) | Trkb-fl based polypeptides and their use in the treatment of alzheimer's disease | |
| Svenningsen et al. | Clinical biomarkers and noninvasive assessment |